Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi has launched a new clinical study titled ‘An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma Who Participated in Study DRI16762.’ The study aims to assess the long-term safety and efficacy of Lunsekimig, a drug designed for adults with moderate-to-severe asthma, highlighting its potential significance in improving asthma management.
The study tests Lunsekimig, an experimental drug administered via subcutaneous injection, intended to provide relief for asthma patients by maintaining long-term safety and efficacy.
This phase 2 interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. Participants who completed a prior study are eligible to join this extension, which spans up to 100 weeks, with treatment lasting up to 96 weeks.
The study began on September 30, 2024, with its last update on July 28, 2025. These dates are crucial as they mark the study’s progression and ongoing recruitment status.
Sanofi’s update on this study could influence its stock performance by showcasing its commitment to advancing asthma treatments. This development may also affect investor sentiment positively, especially in comparison to competitors within the respiratory treatment sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.